Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitavastatin for Reduction of Myocardial Damage in Elective PCI
NCT00786734Phase 4Withdrawn
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Aug 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pitavastatin in stable angina pectoris (2 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoint: Proportion of patients whose CK-MB > 2 times above UNL. Planned start Aug 2008; status: withdrawn.
02
Drugs
pitavastatin
03
Conditions
stable angina pectoris
Beyond the preview
Go deeper on NCT00786734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00786734.